Core Insights - Fortrea has been recognized as a "Leader" in pharmacovigilance operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix Assessment 2025, highlighting its strong position in both pre-and post-approval PV operations [1][2] Company Overview - Fortrea is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [4] - The company offers end-to-end safety solutions that cover the entire product lifecycle, from early clinical phases to post-approval [2][3] Industry Context - The pharmacovigilance landscape is evolving with increased therapeutic complexity, regulatory scrutiny, and patient safety expectations, prompting sponsors to seek service providers that offer integrated scientific insights and strategic support [3] - Fortrea's dual-strength capabilities in clinical-stage safety services and robust post-marketing operations distinguish it in the market, supported by a global Qualified Person Responsible for Pharmacovigilance (QPPV) and technology-led innovations [3] Assessment Details - The Everest Group report evaluated 29 PV operations providers, assessing their service focus, solution offerings, and domain investments through a comprehensive RFI process and client reference checks [2] - Fortrea's strengths in scientific depth, scalability, and global reach have been consistently recognized by clients, contributing to its leadership position in the assessment [3]